

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	<u>General</u>
Otsuka Pharmaceuticals	All Wales Therapeutics and Toxicology
(donidalorsen)	Centre
5	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Allergy UK	Wales
Anaphylaxis Campaign	British National Formulary
Asthma and Lung UK	Care Quality Commission
Genetic Alliance UK	Department of Health - Northern Ireland
HAE UK	Healthcare Improvement Scotland
Immunodeficiency UK	Hospital Information Services –
NARA- The Breathing Charity	Jehovah's Witnesses
South Asian Health Foundation	Medicines and Healthcare products
Specialised Healthcare Alliance	Regulatory Agency
UK Primary Immune-deficiency	National Association of Primary Care
Patient Support Charity (UKPIPS)	National Pharmacy Association
	NHS Confederation
Healthcare professional groups	NHS Wales Joint Commissioning
Association for Respiratory	Committee
Technology and Physiology	Scottish Medicines Consortium
 Association of Genetic Nurses & 	Welsh Government
Counsellors	
Association of Paediatric Emergency	Comparator companies
Medicine	BioCryst Pharmaceuticals (berotralstat)
British Geriatrics Society	CSL Behring (berinert, garadacimab)
British Paediatric Allergy, Immunity	Pharming Group N.V (ruconest)
and Infection Group (BPAIIG)	Takeda (cinryze, lanadelumab)
British Paediatric Respiratory Society	
British Skin Foundation	Relevant research groups
British Society for Allergy & Clinical	Asthma, Allergy and Inflammation
Immunology	Research Trust
British Society for Genetic Medicine	British Association for Lung Research
British Society for Haematology	Cochrane Airways Group
British Society for Immunology	David Hide Asthma and Allergy
British Thoracic Society	Research Centre
BSI Clinical Immunology Professional	Genomics England
Network (BSI-CIPN)	MRC Clinical Trials Unit

Final Stakeholder list for the evaluation of donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]



Sub	bmit or appeal)
 ILD-IN: Interstitial Lung Diseases Interdisciplinary Network Immunology and Allergy Nurses Group 	National Institute for Health Research sociated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Final Stakeholder list for the evaluation of donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]





The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.